To include your compound in the COVID-19 Resource Center, submit it here.

LAX-101: Phase III data

Top-line data from the double-blind, U.S. Phase III ANCHOR trial in 702 patients with fasting triglyceride levels of 200-500 mg/dL who were also on background statin therapy showed that once-daily 2 and

Read the full 329 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE